An organic light-emitting device includes: a first electrode; a second electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1. The organic light-emitting device including the organometallic compound may have a low driving voltage, a high luminance, a high efficiency, and a long lifespan: ##STR00001##

An organic light-emitting device includes: a first electrode; a second electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1. The organic light-emitting device including the organometallic compound may have a low driving voltage, a high luminance, a high efficiency, and a long lifespan: ##STR00001##

A compound comprising a first ligand L.sub.A of Formula I,

##STR00001##

is disclosed. In the structure of Formula I, ring A is a 5-membered or 6-membered carbocyclic or heterocyclic ring, Z.sup.1-Z.sup.4 are each independently C or N; at least two consecutive Z.sup.1-Z.sup.4 are C, and are fused to a structure of Formula II

##STR00002##

or Formula III

##STR00003##

Y.sup.1 and Y.sup.2 are each independently O, S, Se, CRR′, SiRR′, or GeRR′; each R.sup.A, R.sup.B, R.sup.C, R, and R′ is a hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, L.sub.A is complexed to a metal M by the dashed lines in Formula I to form a five-membered chelate ring, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.

A compound comprising a first ligand L.sub.A of Formula I,

##STR00001##

is disclosed. In the structure of Formula I, ring A is a 5-membered or 6-membered carbocyclic or heterocyclic ring, Z.sup.1-Z.sup.4 are each independently C or N; at least two consecutive Z.sup.1-Z.sup.4 are C, and are fused to a structure of Formula II

##STR00002##

or Formula III

##STR00003##

Y.sup.1 and Y.sup.2 are each independently O, S, Se, CRR′, SiRR′, or GeRR′; each R.sup.A, R.sup.B, R.sup.C, R, and R′ is a hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, L.sub.A is complexed to a metal M by the dashed lines in Formula I to form a five-membered chelate ring, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.

The present invention includes novel heteroleptic/homoleptic iridium complexes containing two tridentate ligands, where at least one of the tridentate ligands comprises of pyridinium-derived N-heterocyclic carbene. The compounds of the present invention may be useful for organic electroluminescent devices.

The present invention includes novel heteroleptic/homoleptic iridium complexes containing two tridentate ligands, where at least one of the tridentate ligands comprises of pyridinium-derived N-heterocyclic carbene. The compounds of the present invention may be useful for organic electroluminescent devices.

The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.

The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.